Endothelin-1 induces vasodilation in human skin by nociceptor fibres and release of nitric oxide

British Journal of Clinical Pharmacology

Volumn 45, Issue 5, 1998, Pages 441-446

  Wenzel, René R ^b   Zbinden, Stefan ^b   Noll, Georg ^b   Meier, Bernhard ^b   Lüscher, Thomas F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b NONE

Author keywords

Endothelin 1; Huan skin; Nitric oxide; Nociceptive fibres

Indexed keywords

2 [[2 [[2 [[(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYL]AMINO] 4 METHYLPENTANOYL]AMINO] 3 (1 METHYL 1H INDOL 3 YL)PROPIONYL]AMINO] 3 (2 PYRIDYL)PROPIONIC ACID; ACETYLCHOLINE; BRADYKININ; CAPSAICIN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; NORADRENALIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; HUMAN; HUMAN EXPERIMENT; MALE; NOCICEPTIVE RECEPTOR; NORMAL HUMAN; PRIORITY JOURNAL; SKIN; VASOCONSTRICTION; VASODILATATION;

ADOLESCENT; ADULT; CAPSAICIN; ENDOTHELIN-1; ENZYME INHIBITORS; HUMANS; MALE; MICROCIRCULATION; NITRIC OXIDE; NOCICEPTORS; OMEGA-N-METHYLARGININE; RECEPTORS, ENDOTHELIN; SKIN; VASODILATION;

EID: 0031970308     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00703.x     Document Type: Article

References (37)

1. Yanagisawa M, Kunhara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415.
2. Kurihara Y, Kunhara H, Suzuki H, et al. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 1994; 368: 703-710.
3. Takuwa N, Takuwa Y, Yanagisawa M, Yamashita K, Masaki T. A novel vasoactive peptide endothelm stimulates mitogenesis through inositol lipid turnover in Swiss 3T3 fibroblasts. J Biol Chem 1989; 264: 7856-7861.
4. Kawano Y, Yoshida K, Yoshimi H, Kuramochi M, Omae T. The cardiovascular effect of intracerebroventricular endothelin in rats. J Hypertens 1989; 7(suppl): 522-523.
5. Wenzel RR, Noll G, Lüscher TF. Endothelin receptor antagonists inhibit endothelin in human skin microcirculation. Hypertension 1994; 23: 581-586.
6. Wenzel RR, Duthiers N, Noll G, Bucher J, Kaufmann U, Lüscher TF. Endothelin and calcium antagonists in the skin microcirculation of patients with coronary artery disease. Circulation 1996; 94: 316-322.
7. Lewis T. Experiments relating to cutaneous hyperalgesia and its spread through somatic nerves. Clin Sci 1935; 2: 373-423.
8. Pierau FK, Szolcsanyi J. Neurogenic inflammation: Axon reflex in pigs. Agents and Actions 1989; 26: 231-232.
9. Jancso N, Jancso-Gabor A, Szolcsanyi J. Direct evidence for neurogenic inflammation and its prevention by dencrvation and pretreatment with capsaicin. Br J Pharmacol Chemother 1967; 31: 138-151.
10. de Nucci G, Thomas R, D'Orleans JP, et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA 1988; 85: 9797-9800.
11. Dohi Y, Lüscher TF. Endothelin in hypertensive resistance arteries. Intraluminal and extraluminal dysfunction. Hypertension 1991; 18: 543-549.
12. Bredt DS, Synder SH. Nitric oxide, a novel neuronal messenger. Neuron 1992; 8: 3-11.
13. Stern MD. In vivo evaluation of microcirculation by coherent light scattering. Nature 1975; 254: 56-58.
14. Nilsson GE, Tenland T, Öberg PA. A new instrument for continuous measurement of tissue blood flow by light beating spectroscopy. IEEE Trans Biom Eng 1980; BME-27, No. 1: 12-19.
15. Baynash AG, Hosoda K, Giaid A, et al. Interaction of endothelin-3 with endothelin-B receptor is essential for development of epidermal melanocytes and enteric neurons. Cell 1994; 79: 1277-1285.
16. Takimoto M, Inui T, Okada T, Urade Y. Contraction of smooth muscle by activation of endothelin receptors on autonomic neurons. FEBS Lett 1993; 324: 277-282.
17. Sakurai T, Yanagisawa M, Masaki T. Molecular characterization of endothelin receptors. Trends Pharmacol Sci 1992; 13: 103-108.
18. 2+ mobilization through its specific receptors in murine peritoneal macrophages. FEBS Lett 1991; 280: 103-106.
19. Fujisaki H, Ito H, Hirata Y, et al. Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. J Clin Invest 1995; 96: 1059-1065.
20. Bagnato A, Venuti A, Di Castro V, Marcante ML. Identification of the ETA receptor subtype that mediates endothelin induced autocrine proliferation of normal human keratinocytes. Biochem Biophys Res Commun 1995; 209: 80-86.
21. Touyz RM, Lariviere R, Schiffrin EL. Endothelin influences pHi of human platelets through protein kinase C mediated pathways. Thromb Res 1995; 78: 55-65.
22. Seo B, Oemar BS, Siebenmann R, von Segesser L, Lüscher TF. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 1994; 89: 1203-1208.
23. Uchida Y, Ninomiya H, Sakamoto T, et al. ET-1 released histamine from guinea pig pulmonary but not peritoneal mast cells. Biochem Biophys Res Commun 1992; 189: 1196-1201.
24. Brain SD, Thomas G, Crossman DC, Fuller R, Church MK (1992). Endothelin-1 induces a histamine-dependent flare in vivo, but does not activate human skin mast cells in vitro. Br J Clin Pharmacol 1992; 33: 117-120.
25. Kasakov L, Cellek S, Moncada S. Characterization of nitrergic neurotransmission during short- and long-term electrical stimulation of the rabbit anococcygeus muscle. Br J Pharmacol 1995; 115: 1149-1154.
26. Burnett AL, Lowenstein CJ, Bredt DS, Chang TS, Snyder SH. Nitric oxide: a physiologic mediator of penile erection. Science 1992; 257: 401-403.
27. Rand MJ, Li CG. Modulation of acetylcholine-induced contractions of the rat anococcygeus muscle by activation of nitrergic nerves. Br J Pharmacol 1993; 110: 1479-1482.
28. Anand P, Terenghi G, Warner G, Kopelman P, Williams-Chestnut RE, Sinicropi DV. The role of endogenous nerve growth factor in human diabetic neuropathy. Nature Medicine 1996; 2: 703-707.
29. Pfeifer M, Ross D, Schrage J, et al. A highly successful and novel model for treatment of chronic painful diabetic peripheral neuropathy. Diabetes Care, 1993; 16: 1103-1115.
30. Treatment of painful diabetic neuropathy with topical capsaicin. A multicenter, double-blind, vehicle-controlled study. The Capsaicin Study Group. Arch Intern Med 1991; 151: 2225-2229.
31. Tandan R, Lewis G, Badger G, Fries T. Topical capsaicin in painful diabetic neuropathy. Effect on sensory function. Diabetes Care 1992; 15: 15-18.
32. Peikert A, Hentrich M, Ochs G. Topical 0.025% capsaicin in chronic post-herpetic neuralgia: efficacy, predictors of response and long-term course. J Neurol 1991; 238: 452-456.
33. Watson C, Tyler K, Bickers D, Millikan L, Smith S, Coleman E. A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia. Clin Ther 1993; 15: 510-526.
34. Ellis C, Berberian B, Sulica V, et al. A double-blind evaluation of topical capsaicin in pruntic psoriasis. J Am Acad Dermatol 1993; 29: 438-442.
35. Deal C, Schnitzer T, Lipstein E, et al. Treatment of arthritis with topical capsaicin: a double-blind trial. Clin Ther 1991; 13: 383-395.
36. Fusco B, Marabini S, Maggi C, Fiore G, Geppetti P. Preventative effect of repeated nasal applications of capsaicin in cluster headache. Pain 1994; 59: 321-325.
37. Muhiddin K, Gallen I, Harries S, Pearce V. The use of capsaicin cream in a case of erythromelalgia. Postgrad Med J 1994; 70: 841-843.